CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025
CytomX Therapeutics (NASDAQ: CTMX), a company specializing in masked, conditionally activated biologics, has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT following the announcement.
Interested participants can access the live webcast through CytomX's investor relations website and are advised to register for the conference call at least 10 minutes before it begins. A replay of the webcast will be made available on the company's website after the event.
CytomX Therapeutics (NASDAQ: CTMX), azienda specializzata in biologici mascherati e attivati condizionalmente, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per lunedì 12 maggio 2025, prima dell'apertura dei mercati statunitensi. La società terrà una conference call e una webcast alle 8:00 a.m. ET / 5:00 a.m. PT subito dopo l'annuncio.
I partecipanti interessati potranno seguire la diretta streaming attraverso il sito web delle relazioni con gli investitori di CytomX e sono invitati a registrarsi per la conference call almeno 10 minuti prima dell'inizio. Una registrazione della webcast sarà disponibile sul sito aziendale dopo l'evento.
CytomX Therapeutics (NASDAQ: CTMX), una empresa especializada en biológicos enmascarados y activados condicionalmente, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el lunes 12 de mayo de 2025, antes de la apertura de los mercados de EE. UU. La compañía realizará una llamada de conferencia y una transmisión en vivo a las 8:00 a.m. ET / 5:00 a.m. PT tras el anuncio.
Los interesados pueden acceder a la transmisión en vivo a través del sitio web de relaciones con inversionistas de CytomX y se recomienda registrarse para la llamada de conferencia al menos 10 minutos antes de que comience. Una repetición de la transmisión estará disponible en el sitio web de la empresa después del evento.
CytomX Therapeutics (NASDAQ: CTMX)는 마스크 처리된 조건부 활성 생물학 제제 전문 회사로, 2025년 1분기 재무 결과 발표를 2025년 5월 12일 월요일 미국 시장 개장 전으로 예정했습니다. 회사는 발표 후 동부 시간 오전 8시 / 태평양 시간 오전 5시에 컨퍼런스 콜 및 웹캐스트를 진행할 예정입니다.
참석을 원하는 분들은 CytomX 투자자 관계 웹사이트를 통해 라이브 웹캐스트에 접속할 수 있으며, 컨퍼런스 콜 시작 10분 전까지 등록할 것을 권장합니다. 웹캐스트 녹화본은 행사 후 회사 웹사이트에서 제공될 예정입니다.
CytomX Therapeutics (NASDAQ : CTMX), une société spécialisée dans les biologiques masqués et activés conditionnellement, a prévu d’annoncer ses résultats financiers du premier trimestre 2025 le lundi 12 mai 2025, avant l’ouverture des marchés américains. La société organisera une conférence téléphonique et une diffusion en direct à 8h00 ET / 5h00 PT après l’annonce.
Les participants intéressés peuvent accéder à la diffusion en direct via le site des relations investisseurs de CytomX et sont invités à s’inscrire à la conférence téléphonique au moins 10 minutes avant le début. Un replay de la diffusion sera disponible sur le site de la société après l’événement.
CytomX Therapeutics (NASDAQ: CTMX), ein Unternehmen, das sich auf maskierte, bedingt aktivierte Biologika spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Montag, den 12. Mai 2025, vor Öffnung der US-Märkte geplant. Das Unternehmen wird im Anschluss an die Bekanntgabe eine Telefonkonferenz und einen Webcast um 8:00 Uhr ET / 5:00 Uhr PT veranstalten.
Interessierte Teilnehmer können den Live-Webcast über die Investor-Relations-Website von CytomX verfolgen und werden gebeten, sich mindestens 10 Minuten vor Beginn der Telefonkonferenz anzumelden. Eine Aufzeichnung des Webcasts wird nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Monday, May 12, 2025, before the open of the U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT.
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engagers, and immune modulators such as cytokines. CytomX’s clinical-stage pipeline includes CX-2051 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM), armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers, including CRC, and was discovered in collaboration with ImmunoGen, now part of AbbVie. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com
FAQ
When will CytomX Therapeutics (CTMX) report Q1 2025 earnings?
What time is the CytomX Therapeutics Q1 2025 earnings call?
How can I access CytomX Therapeutics' Q1 2025 earnings call?
Will there be a replay available of CytomX's Q1 2025 earnings call?
